Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00193973
Recruitment Status : Completed
First Posted : September 19, 2005
Last Update Posted : February 17, 2017
Australasian Leukaemia and Lymphoma Group
Information provided by (Responsible Party):
Trans-Tasman Radiation Oncology Group (TROG)

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : July 2008
  Study Completion Date : August 2013